ACAN and juvenile idiopathic arthritis: Taking into consideration the above-mentioned relations, the present quantitative evaluation of both CS, as an early marker of aggrecan degradation, and chondroitin sulfate 846 epitope (CS846), as a biomarker of aggrecan synthesis, is an attempt at answering the question whether the therapy used in JIA patients, whose purpose is to reduce the inflammatory and immunological parameters of the disease activity, simultaneously contributes to the normalization of biochemical changes in aggrecan and thus inhibits the dysfunction of articular cartilage.